Results
A total of 316 subjects were recruited for the study, 251
subjects completed a baseline HS-Omega-3 Index assessment,
and 157 subjects completed all aspects of the trial
through 120 days. Non-completers were lost to follow-up.
Adverse events reported were not serious and were determined
to not be associated with the study product. The
mean age of subjects was 44.3 ± 0.9 years. Table 1 provides
information on omega-3 supplement usage at baseline. No
other demographic data were obtained.
The HS-Omega-3 Index increased from 6.1% (range of
3.1-11.8%) at baseline to 7.3% (3.7-13.3%) at 120 days
(p < 0.001, Figure 1). This represents an approximate
20% increase over baseline. The baseline score of approximately
6% was higher than previously reported
baseline scores of approximately 4%, as expected,
reflecting regular use of omega-3 fatty acid supplements
[24,25]. The mental composite score increased
after 60 days and remained elevated through day 120